{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:26:40Z","timestamp":1790137600777,"version":"4.0.1"},"reference-count":68,"publisher":"Centers for Disease Control MMWR Office","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr6804a1","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:26:24Z","timestamp":1576149984000},"page":"1-14","source":"Crossref","is-referenced-by-count":53,"title":["Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019"],"prefix":"10.15585","volume":"68","author":[{"given":"William A.","family":"Bower","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarad","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur M.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad P.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R1","first-page":"176","article-title":"A major epidemic of anthrax in Zimbabwe. The experience at the Beatrice Road Infectious Diseases Hospital, Harare.","volume":"31","author":"Davies","year":"1985","journal-title":"Cent Afr J Med"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005.","volume":"144","author":"Holty","year":"2006","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/cid\/ciw184","article-title":"Identifying meningitis during an anthrax mass casualty incident: systematic review of systemic anthrax since 1880.","volume":"62","author":"Katharios-Lanwermeyer","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(10)60573-9","article-title":"Anthrax infection in drug users.","volume":"375","author":"Booth","year":"2010","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R5","unstructured":"US Department of Agriculture; CDC. Federal Select Agent Program: select agents and toxins FAQS. Washington, DC: US Department of Agriculture; Atlanta, GA: CDC. https:\/\/www.selectagents.gov\/faq-general.html"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R6","unstructured":"US Food and Drug Administration. Full prescribing information: BioThrax (Anthrax Vaccine Adsorbed). Silver Spring, MD: US Food and Drug Administration. https:\/\/www.fda.gov\/media\/71954\/download"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R7","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation.","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R9","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R10","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of anthrax vaccine adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R11","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1016\/j.vaccine.2014.01.096","article-title":"Enhanced early innate and T cell-mediated responses in subjects immunized with anthrax vaccine adsorbed plus CPG 7909 (AV7909).","volume":"32","author":"Minang","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R12","doi-asserted-by":"publisher","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax\u00ae (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.coviro.2012.01.004","article-title":"Licensure of vaccines using the Animal Rule.","volume":"2","author":"Burns","year":"2012","journal-title":"Curr Opin Virol"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R14","unstructured":"US Food and Drug Administration. Product development under the Animal Rule. Silver Spring, MD: US Food and Drug Administration. https:\/\/www.fda.gov\/media\/88625\/download."},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/pds.1213","article-title":"Development of the Vaccine Analytic Unit\u2019s research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed.","volume":"16","author":"Payne","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R16","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R17","unstructured":"CDC. GRADE (Grading of Recommendations, Assessment, Development and Evaluation). Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R18","unstructured":"CDC. ACIP meeting information. Atlanta, GA: US Department of Health and Human Services, CDC. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/index.html"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3201\/eid0810.020223","article-title":"Epidemiologic response to anthrax outbreaks: field investigations, 1950\u20132001.","volume":"8","author":"Bales","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.4269\/ajtmh.2007.77.1103","article-title":"Modeling the geographic distribution of Bacillus anthracis, the causative agent of anthrax disease, for the contiguous United States using predictive ecological [corrected] niche modeling.","volume":"77","author":"Blackburn","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R21","unstructured":"Anthrax in humans. In: World Health Organization. Anthrax in humans and animals. 4th ed. Geneva, Switzerland; World Health Organization; 2008:36\u201352. https:\/\/www.who.int\/csr\/resources\/publications\/anthrax_webs.pdf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R22","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.1997.03550050074036","article-title":"Biological warfare: a historical perspective.","volume":"278","author":"Christopher","year":"1997","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/scientificamerican1296-60","article-title":"The specter of biological weapons.","volume":"275","author":"Cole","year":"1996","journal-title":"Sci Am"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jama.1997.03550050080037","article-title":"Iraq\u2019s biological weapons: the past as future?","volume":"278","author":"Zilinskas","year":"1997","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R26","unstructured":"World Health Organization. Health aspects of chemical and biological weapons, report of a WHO group of consultants. Geneva, Switzerland; World Health Organization; 1970."},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R27","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687","article-title":"Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults.","volume":"20","author":"Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R28","article-title":"Clinical framework and medical countermeasure use during an anthrax mass-casualty incident: CDC recommendations.","volume":"64","author":"Bowere","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey.","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R30","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax.","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R31","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1073\/pnas.0602748103","article-title":"Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.","volume":"103","author":"Vietri","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R32","unstructured":"US Food and Drug Administration. Pathway to licensure for protective antigen-based anthrax vaccines for a post-exposure prophylaxis indication using the Animal Rule: briefing document for the Vaccines and Related Biological Products Advisory Committee Meeting. Silver Spring, MD: US Food and Drug Administration; November 16, 2010. http:\/\/wayback.archive-it.org\/7993\/20170113080506\/http:\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/UCM232400.pdf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R33","doi-asserted-by":"publisher","first-page":"151ra126","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R34","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1016\/j.vaccine.2015.05.091","article-title":"Bridging non-human primate correlates of protection to reassess the anthrax vaccine adsorbed booster schedule in humans.","volume":"33","author":"Schiffer","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.vaccine.2013.10.039","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.","volume":"32","author":"Wright","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R36","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1016\/j.vaccine.2016.04.048","article-title":"Evaluation of early immune response-survival relationship in cynomolgus macaques after anthrax vaccine adsorbed vaccination and Bacillus anthracis spore challenge.","volume":"34","author":"Sivko","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R37","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1016\/j.vaccine.2014.08.076","article-title":"Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.","volume":"32","author":"Bernstein","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R38","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1016\/j.vaccine.2016.06.041","article-title":"Cross-species prediction of human survival probabilities for accelerated anthrax vaccine adsorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.","volume":"34","author":"Stark","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R39","unstructured":"US Food and Drug Administration. Summary basis for regulatory action\u2014BioThrax (Anthrax Vaccine Adsorbed). Silver Spring, MD: US Food and Drug Administration; 2015. https:\/\/www.fda.gov\/media\/94823\/download"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R40","unstructured":"US Food and Drug Administration. 21 CFR Sec. 310.305 Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications. Federal Register 2018;5. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=310.305"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/pds.1657","article-title":"Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.","volume":"17","author":"Zhang","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R42","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R43","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.vaccine.2014.01.073","article-title":"Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax\u00ae regimen for post-exposure prophylaxis in healthy adults.","volume":"32","author":"Hopkins","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R44","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/j.vaccine.2015.03.071","article-title":"Evaluation of anthrax vaccine safety in 18 to 20 year olds: a first step towards age de-escalation studies in adolescents.","volume":"33","author":"King","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R45","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","article-title":"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.","volume":"34","author":"Hopkins","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R46","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1016\/j.vaccine.2012.06.076","article-title":"Health-related quality of life in the CDC anthrax vaccine adsorbed human clinical trial.","volume":"30","author":"Stewart","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R47","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.vaccine.2009.03.091","article-title":"Antibodies to squalene in U.S. Navy Persian Gulf War veterans with chronic multisymptom illness.","volume":"27","author":"Phillips","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R48","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1016\/j.vaccine.2012.07.067","article-title":"Disability among U.S. Army veterans vaccinated against anthrax.","volume":"30","author":"Sulsky","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R49","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1016\/j.vaccine.2011.06.028","article-title":"Risk of disability for U.S. Army personnel vaccinated against anthrax, 1998\u20132005.","volume":"29","author":"Sulsky","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R50","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.vaccine.2011.10.087","article-title":"Vaccination and risk of type 1 diabetes mellitus in active component U.S. military, 2002\u20132008.","volume":"30","author":"Duderstadt","year":"2012","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/21645515.2018.1549453","article-title":"Vaccination and risk of lone atrial fibrillation in the active component United States military.","volume":"15","author":"McNeil","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R52","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.7205\/MILMED-D-15-00485","article-title":"Anthrax vaccine and the risk of rheumatoid arthritis and systemic lupus erythematosus in the U.S. military: a case-control study.","volume":"181","author":"Bardenheier","year":"2016","journal-title":"Mil Med"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R53","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1016\/j.vaccine.2015.05.054","article-title":"Analysis of pregnancy and infant health outcomes among women in the National Smallpox Vaccine in Pregnancy Registry who received anthrax vaccine adsorbed.","volume":"33","author":"Conlin","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R54","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1016\/j.vaccine.2017.06.032","article-title":"Safety of inadvertent anthrax vaccination during pregnancy: an analysis of birth defects in the U.S. military population, 2003\u20132010.","volume":"35","author":"Conlin","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R55","unstructured":"US Food and Drug Administration. Emergency use authorization of medical products and related authorities. Silver Spring, MD: US Food and Drug Administration; 2017. https:\/\/www.fda.gov\/media\/97321\/download"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R56","unstructured":"National Institutes of Health. A phase 2 safety and immunogenicity study for an anthrax vaccine using 3 schedules and two dose levels. Washington, DC: National Institutes of Health; 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01770743?view=results"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study.","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R58","doi-asserted-by":"publisher","first-page":"e8787","DOI":"10.1371\/journal.pone.0008787","article-title":"Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1\/Alhydrogel with and without CPG 7909 in malaria na\u00efve adults.","volume":"5","author":"Ellis","year":"2010","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R59","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R60","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.","volume":"19","author":"Cooper","year":"2005","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R61","doi-asserted-by":"publisher","first-page":"e2940","DOI":"10.1371\/journal.pone.0002940","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.","volume":"3","author":"Mullen","year":"2008","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R62","unstructured":"US National Library of Medicine. BARDA Securing Anthrax Immunity For the Elderly (B-SAFE) study. Bethesda, MD: US National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03518125?cond=AV7909&draw=1&rank=3"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R63","unstructured":"Anthim. Package insert. Pine Brook, NJ: Elusys Therapeutics; 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125509lbl.pdf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R64","unstructured":"Raxibacumab. Package insert. Rockville, MD: GlaxoSmithKline; 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125349s000lbl.pdf"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R65","unstructured":"Anthrasil. Package insert. Manitoba, Canada: Emergent BioSolutions; 2015. https:\/\/www.fda.gov\/media\/91577\/download."},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax.","volume":"361","author":"Migone","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R67","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1128\/AAC.01102-16","article-title":"Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax.","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr6804a1-201912121126-R68","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1128\/AAC.00460-13","article-title":"Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.","volume":"57","author":"Malkevich","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T11:26:31Z","timestamp":1576149991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/68\/rr\/rr6804a1.htm?s_cid=rr6804a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,13]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr6804a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,13]]},"published":{"date-parts":[[2019,12,13]]}}}